Muhammad Bergas Nur Fayyad

Muhammad Bergas Nur Fayyad

Auto-generated profile, based on publicly available information

Muhammad Bergas Nur Fayyad

Radboud university medical center Nijmegen The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
CJCe Jiang
Ce Jiang
CBCéline Beji
Céline Beji
SZSonia Zebachi
Sonia Zebachi
GHGhinwa Y. Hayek
Ghinwa Y. Hayek
ACAysun Cetinyurek‐Yavuz
Aysun Cetinyurek‐Yavuz
JTJulien Tanniou
Julien Tanniou
The decision‐making process in drug development involves “go/no‐go” decisions, particularly at the transition from early to late‐stage trials. While the decisions are solely made by drug developers, they must take into account the perspectives of multiple stakeholders—such as regulatory agencies, HTA bodies, payers, patients, and ethics committees—to ensure well‐informed and robust decision‐making. These perspectives influence key considerations, including resource allocation, risk mitigation, regulatory compliance, etc. To support this process, quantitative methodologies, including Bayesian and hybrid frequentist‐Bayesian approaches, have been introduced to improve decision‐making. However, these methodologies often do not fully account for the diverse priorities and needs of all stakeholders. This scoping review examines criteria and methods used in decision‐making at the phase II to III transition, with a focus on broadening the probability of success (PoS) concept beyond efficacy alone. Our review explores PoS for different success definitions, such as regulatory approval, market access, financial viability, and competitive performance. Key themes include decision criteria selection, trial design optimization, utility‐based approaches, financial metrics, and multi‐stakeholder considerations in decision‐making. Our findings highlight both the limitations of current methodologies and potential paths forward, including the integration of real‐world data (RWD) and advanced analytics. This work complements a companion manuscript by Cetinyurek‐Yavuz et al. (2025) providing a detailed review of PoS methodologies focused solely on efficacy, specifically PoS for achieving statistical significance in phase III studies, including definitions, terminologies, and analytical approaches. Together, these studies provide a foundation for advancing late‐stage trial decisions toward a more balanced, data‐driven, and stakeholder‐aligned approach.

24 January 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
AYAysun Cetinyurek Yavuz
Aysun Cetinyurek Yavuz
MFMuhammad Bergas Nur Fayyad
Muhammad Bergas Nur Fayyad
CJCe Jiang
Ce Jiang
FBFlorie Brion Bouvier
Florie Brion Bouvier
CBCeline Beji
Celine Beji
LRLaura Rodwell
Laura Rodwell
Drug development is a lengthy process with considerable uncertainty at each milestone. Several trials are needed to progress to confirmatory evaluation and establish a positive benefit–risk balance. One of the critical milestones is the decision to progress to phase III based on phase II trial results. Use of probability of success is becoming standard in pharmaceutical companies to support this decision. However, the lack of consistency in terminology makes it difficult to assess the comparative value of different approaches. By leveraging the availability of high‐quality external data (e.g., real‐world data, historical clinical trial data, etc.), probability of success‐based procedures may further improve decision‐making. We performed a scoping review of approaches to calculate the probability of success of a phase III trial depending on the available data sources and the availability of specific endpoints. Calculation of probability of success is relatively straightforward if data for the primary endpoint of the phase III trial are also available in phase II trials. Often, phase II trials are based on biomarker or surrogate outcomes, due to challenges associated with study duration and required sample size. Probability of success‐based procedures as reviewed can incorporate external data sources, for example, from clinical trials testing the same or similar drug or real‐world data on the targeted population—optimizing the calculation of probability of trial success and the projected drug candidate value. We conclude the paper by reflecting on alternative approaches and ideas for uses within pharmaceutical companies and academia.